Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, superiority phase IIa trial to assess
the safety and efficacy of dupilumab use in hospitalized patients with moderate to severe
COVID-19 infection.
Phase:
Phase 2
Details
Lead Sponsor:
University of Virginia
Collaborators:
PBM C19 Research, LLC (a COVID-19 research entity of the Paul Manning Foundation) PBM C19 Research, LLC (PBM) Virginia Catalyst, Virginia Biosciences Health Research Corporation (VBHRC)